Evidence map›Paper›PMID 33962640›Full record

ArticleBioData mining2021

A prognostic model based on seven immune-related genes predicts the overall survival of patients with hepatocellular carcinoma.

Qian Yan, Wenjiang Zheng, Boqing Wang, Baoqian Ye, Huiyan Luo, Xinqian Yang, Ping Zhang, Xiongwen Wang

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in BioData mining, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Stanniocalcin 2 (STC2): a universal tumour biomarker and a potential therapeutical target.Journal of experimental & clinical cancer research : CR · 2022
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Qian Yan *The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
Wenjiang Zheng *The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
Boqing Wang *The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
Baoqian YeThe First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
Huiyan LuoThe First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
Xinqian YangThe First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
Ping ZhangThe First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
Xiongwen WangDepartment of Oncology, The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China. awen681029@163.com.ORCID http://orcid.org/0000-0002-5428-7110
Guangzhou University of Chinese Medicine · CNFirst Affiliated Hospital of Guangzhou University of Chinese Medicine · CN

Funding

2020 National College Student Innovation and Entrepreneurship Training Program of Guangzhou University of Chinese Medicine S202010572123Guangzhou University of Chinese Medicine National University Student Innovation and Entrepreneurship Training Project 201810572038R & D projects in key areas of Guangdong Province, Construction of high-level university in Guangzhou University of Chinese Medicine A1-AFD018181A29the First Affiliated Hospital of Guangzhou University of Chinese Medicine Innovation and Student Training Team Incubation Project 2018XXTD003
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is a disease with a high incidence and a poor prognosis. Growing amounts of evidence have shown that the immune system plays a critical role in the biological processes of HCC such as progression, recurrence, and metastasis, and some have discussed using it as a weapon against a variety of cancers. However, the impact of immune-related genes (IRGs) on the prognosis of HCC remains unclear.

methodsBased on The Cancer Gene Atlas (TCGA) and Immunology Database and Analysis Portal (ImmPort) datasets, we integrated the ribonucleic acid (RNA) sequencing profiles of 424 HCC patients with IRGs to calculate immune-related differentially expressed genes (DEGs). Survival analysis was used to establish a prognostic model of survival- and immune-related DEGs. Based on genomic and clinicopathological data, we constructed a nomogram to predict the prognosis of HCC patients. Gene set enrichment analysis further clarified the signalling pathways of the high-risk and low-risk groups constructed based on the IRGs in HCC. Next, we evaluated the correlation between the risk score and the infiltration of immune cells, and finally, we validated the prognostic performance of this model in the GSE14520 dataset.

resultsA total of 100 immune-related DEGs were significantly associated with the clinical outcomes of patients with HCC. We performed univariate and multivariate least absolute shrinkage and selection operator (Lasso) regression analyses on these genes to construct a prognostic model of seven IRGs (Fatty Acid Binding Protein 6 (FABP6), Microtubule-Associated Protein Tau (MAPT), Baculoviral IAP Repeat Containing 5 (BIRC5), Plexin-A1 (PLXNA1), Secreted Phosphoprotein 1 (SPP1), Stanniocalcin 2 (STC2) and Chondroitin Sulfate Proteoglycan 5 (CSPG5)), which showed better prognostic performance than the tumour/node/metastasis (TNM) staging system. Moreover, we constructed a regulatory network related to transcription factors (TFs) that further unravelled the regulatory mechanisms of these genes. According to the median value of the risk score, the entire TCGA cohort was divided into high-risk and low-risk groups, and the low-risk group had a better overall survival (OS) rate. To predict the OS rate of HCC, we established a gene- and clinical factor-related nomogram. The receiver operating characteristic (ROC) curve, concordance index (C-index) and calibration curve showed that this model had moderate accuracy. The correlation analysis between the risk score and the infiltration of six common types of immune cells showed that the model could reflect the state of the immune microenvironment in HCC tumours.

conclusionOur IRG prognostic model was shown to have value in the monitoring, treatment, and prognostic assessment of HCC patients and could be used as a survival prediction tool in the near future.

Indexed as

Hepatocellular carcinomaImmune infiltrationImmune-related genesNomogramPrognostic model

Identifiers

PMID33962640
PMCPMC8106157
OpenAlexW3159161611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.